Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28100325 | 0.81 | ALDH1A1 (0.41) | NOS2ALDH1A1ACACBLMNAHTT | |
| Isopropyl Alcohol SCHEMBL7083853 | 0.79 | ROCK2 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5158384 | 0.78 | ACACB (0.41) | MEN1KMT2ANOS2ALDH1A1ACACB | |
| Water SCHEMBL11246942 | 0.76 | ALDH1A1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL659350 | 0.74 | ACACB (0.50) | NOS2ACACB | |
| SCHEMBL369224 | 0.73 | NAMPT (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31258555 | 0.73 | — | — | |
| SCHEMBL1641505 | 0.73 | — | — | |
| SCHEMBL13531256 | 0.72 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5933826 | 0.72 | CA12 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| EP-3400223-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017118689-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | CA12 3862/4885CA1 2610/4885CA2 1851/4885 |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | CA12 3862/4885CA1 2610/4885CA2 1851/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | CA12 4320/4885CA1 3506/4885CA2 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.